Gut bacteria and liver cancer treatment study
Part of Cancer, Digestive system clinical trials.
This study looks at how the bacteria in your gut (microbiome) affect liver cancer treatment. It aims to learn if certain gut bacteria can predict how well the combination of targeted therapy and immunotherapy works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- Your cancer is at stage B or C (BCLC stage).
- You have not received systemic treatment (like chemotherapy or targeted therapy) for this cancer before.
- Your tumor cannot be removed by surgery (irremovable).
- You are scheduled to receive a combination of a targeted anti-angiogenic drug and an immune checkpoint inhibitor.
- You have at least one measurable tumor lesion (as per RECIST 1.1).
- You have a good performance status (ECOG 0 or 1), meaning you are up and about more than half the day.
- You agree to join voluntarily, sign the consent form, and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut (microbiome) might affect treatment for liver cancer. It tests a combination of targeted therapy and immunotherapy, which are already approved for liver cancer. The goal is to see if gut bacteria can predict how well the treatment works.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This study looks at the bacteria in your gut (microbiome) and how your body responds to liver disease. Researchers want to learn if these factors can help improve care for people with liver problems.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.